Seattle Genetics' Siegall `Excited' by Cancer Drug Data: Video
702 views · Published 23 March 2012 · 4:39 · Indexed 22 September 2026
Channel: Bloomberg Originals · 2012 · Entertainment
Oct. 11 (Bloomberg) -- Clay Siegall, chief executive officer of Seattle Genetics Inc., discusses the results from a clinical trial of its SGN-35 drug for treating anaplastic large cell lymphoma.
The drug, also known as brentuximab vedotin, uses an antibody to home in on cancer cells. Siegall, speaking with Betty Liu and Adam Johnson on Bloomberg Television's "In the Loop," also discusses the prospects that his company may become a takeover target. (Source: Bloomberg)
More from this channel
-
3:30
Market Close 6.4 - Bloomberg
-
0:17
Pens Tie Stanley Cup Series - Bloomberg
-
0:35
Hardware Price Too High - Activision - Bloomberg
-
0:31
FDIC Seeks Citigroup Shares-Up - WSJ - Bloomberg
-
0:44
Bank Have More Accounting Leeway - Bloomberg
-
0:32
Lakers Beat Magic 100-75 - Bloomberg
-
0:30
Johnson Wins 300th Game - Bloomberg
-
1:13
GM Expects To Sell Saturn To Penske Automotive - Bloomberg